Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FLOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN EXTENDED RELEASE versus FLOXIN.
CIPROFLOXACIN EXTENDED RELEASE vs FLOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
Inhibition of bacterial DNA gyrase and topoisomerase IV, preventing DNA replication, transcription, repair, and recombination.
500-1000 mg orally once daily for 7-14 days; extended-release tablet must be taken whole with a meal.
400 mg orally every 12 hours for 10-14 days; ophthalmic solution: 1-2 drops in affected eye(s) every 2-4 hours for 2 days, then 1-2 drops 4 times daily for 10 days; otic solution: 5-10 drops in affected ear(s) twice daily for 10-14 days.
None Documented
None Documented
Terminal elimination half-life approximately 11 hours, ranging from 10-14 hours in patients with normal renal function. Prolonged in renal impairment; requires dose adjustment.
Terminal elimination half-life of 10-14 hours in patients with normal renal function; prolonged in renal impairment (up to 40-50 hours in severe cases).
Primarily renal excretion (50-70% unchanged drug via glomerular filtration and tubular secretion); 15-25% metabolized; 20-35% fecal elimination via biliary secretion and intestinal epithelium.
Approximately 70-90% excreted unchanged in urine via glomerular filtration and tubular secretion; about 10-30% eliminated in feces via biliary excretion.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic